Wanbury Limited
Incorporated in 1988, Wanbury Ltd is in the business of pharmaceutical and related activities, including research
What Wanbury files
- Others58
- Updates34
- Board Meeting18
- Important7
- PPTs5
- Insider Trade5
Wanbury delivered a strong performance for FY26, signaling a successful business turnaround. Revenue grew 8% YoY to ₹650.27 Cr, while Profit After Tax (PAT) surged 117% YoY to ₹66.13 Cr. EBITDA rose 35% YoY to ₹107.69 Cr, with margins improving significantly to 16.6%. Basic EPS hit ₹20.55, up 120% YoY....
Wanbury Ltd. has scheduled a physical plant visit and management meeting for investors and analysts on June 5, 2026. This event is a key recent development, offering a direct look at company operations. During the meeting, discussions will focus on past financial results and information already available in the public...
Wanbury delivered a strong Q3FY26, with revenue growing 22% YoY to ₹162 Cr. For 9MFY26, revenue increased 14% YoY to ₹486 Cr. Both API (₹424 Cr, +14% YoY for 9MFY26) and Formulations (₹62 Cr, +9% YoY for 9MFY26) segments showed healthy demand, with Formulations achieving positive EBITDA for the period....
Wanbury delivered a robust H1 FY26 with revenue up 10.6% YoY to ₹323.2 Cr and PAT soaring 216.5% YoY to ₹28.67 Cr. Q2 FY26 also saw impressive PAT growth of 89% YoY to ₹15.18 Cr, with basic EPS rising 88% YoY to ₹4.58, alongside a slight revenue dip to ₹160.06...
Wanbury had a solid H1FY26! Revenue jumped 10.6% YoY to ₹323.2 Cr, with PAT skyrocketing 216.45% YoY to ₹28.67 Cr. EBITDA hit ₹50.77 Cr (+51.26% YoY), boosting margins to 15.71%. The API segment grew 8.2% YoY, while Formulations surged 17.6% YoY and achieved EBITDA positivity. Growth strategy focuses on launching...